MEMP PhD Thesis Defense (3:00pm): Rumya Raghavan

Engineering minimally immunogenic cargos and delivery modalities for gene therapy

Since the discovery of CRISPR-Cas9 systems, gene therapies have revolutionized the field of molecular biology by introducing functional genes into cells to correct genetic defects or diseases. To date, several gene therapies are pending approval for use in the clinic and have shown promise in the treatment of a variety of genetic disorders including retinal dystrophy, hemophilia, lysosomal storage disorders and certain types of cancer. However, there are several challenges to using CRISPR-Cas9 in the clinic, including the efficiency and specificity of the gene editing process, the potential for off-target effects, and the immunogenicity of the CRISPR-Cas9 system. One of the main challenges of gene therapies is the immunogenicity of the (1) therapeutic vector and (2) cargo. Existing delivery systems trigger immune responses, rendering therapies ineffective and pose considerable risks to the patient population. Even the cargos, Cas nucleases, have been shown to generate humoral and cellular immunity in the general population. Thus, there is a need for minimally immunogenic cargos and delivery modalities to advance gene therapy to the clinic. 

The goal of this thesis is to design and optimize minimally immunogenic (1) vehicles and (2) cargos for translational gene therapy delivery. (1) For the development of gene therapy delivery vectors, previous work has identified endogenous proteins that can form capsids and package nucleic acid. In this work, I focus on the PNMA or Paraneoplastic MA-containing protein family to engineer a delivery system that can form capsids, package nucleic acid, and deliver functional, minimally immunogenic cargo to target cells. (2) For the development of non-immunogenic gene therapy cargos, I engineer existing gene therapy cargos, such as SaCas9 and AsCas12a, to be minimally immunogenic while retaining native functionality.

This work overall highlights the promise of protein engineering to minimize immunogenicity of delivery systems and gene editing nucleases while optimizing for their functionality in vivo. I hope this work will be expanded and grow to serve as a foundation for personalized gene therapy medicine.

Thesis Supervisor:
Feng Zhang, PhD
James and Patricia Poitras Professor of Neuroscience, MIT; Core Member of the Broad Institute

Thesis Committee Chair:
Jim Collins, PhD
Termeer Professor of Medical Engineering and Science, Broad Institute of MIT and Harvard

Thesis Reader:
Michael Birnbaum, PhD
Class of 1856 Development Professor. MIT; Member of the Koch Institute
------------------------------------------------------------------------------------------------------

Zoom invitation –

Rumya Raghavan is inviting you to a scheduled Zoom meeting.

Topic: Rumya Raghavan Thesis Defense
Time: Friday, September 15, 2023, 3:00 PM Eastern Time (US and Canada)

Your participation is important to us: please notify hst [at] mit.edu (hst[at]mit[dot]edu), at least 3 business days in advance, if you require accommodations in order to access this event.

Join Zoom Meeting
https://broadinstitute.zoom.us/j/82593566074

Meeting ID:  825 9356 6074
Passcode: REDICAS9

One tap mobile
+16465588656,,82593566074#,,,,*41497150# US (New York)
+16468769923,,82593566074#,,,,*41497150# US (New York)

Dial by your location
+1 646 558 8656 US (New York)
+1 646 876 9923 US (New York)

Meeting ID:  825 9356 6074
Passcode: 41497150

Find your local number: https://broadinstitute.zoom.us/u/kbssPP11zo